---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000013"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:32:05.601714+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma reports FY 2023 results; aligns with FDA on Phase 3 migraine design

## Summary
- End-of-Phase 2 meeting with FDA achieved alignment on pivotal Phase 3 trial design for episodic and chronic migraine.
- Phase 2 chronic migraine study completed enrollment (492 patients); interim analysis data expected Q2 2024.
- Announced $15M private placement of senior secured convertible notes with Daewoong; first $5M closed, second $10M due April 2024.
- Cash runway projected through June 2024 only; company to fund late-stage clinical development.
- No financial results provided in press release beyond qualitative business update.

## SEC filing metadata
- accession: 0001837607-24-000013
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/0001837607-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/aeon-20240329x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000013
- JSON: https://secwatch.observer/filing/0001837607-24-000013.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000013.txt

## Key facts
- Earnings Releases
  AEON Biopharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/0001837607-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.